We are live on ! Find out more
PRTK

Paratek Pharmaceuticals

Delisted

PRTK was delisted on the 20th of September, 2023.

90 hedge funds and large institutions have $245M invested in Paratek Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

560% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 5

443% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 7

254% more capital inflows, than outflows

Capital inflows: $69M | Capital outflows: $19.5M

57% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $1.33M

45% more funds holding

Funds holding: 62 → 90 (+28)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

2.31% less ownership

Funds ownership: 79.56% → 77.25% (-2.3%)

Holders
90
Holders Change
+28
Holders Change %
+45.16%
% of All Funds
2.4%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.11%
New
33
Increased
38
Reduced
7
Closed
5
Calls
$2.08​M
Puts
$1.33​M
Net Calls
+$752​K
Net Calls Change
+$470​K

PRTK Hedge Fund Activity: Q2 2016 in Review

90 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals (PRTK) for Q2 2016, worth a combined $245M — up 14% from $214M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PRTK positions and 5 closed out — a net gain of 28 holders — while 38 added to existing stakes and 7 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $8.47M. The largest seller was Fidelity Investments, cutting an estimated $7.32M.

  • 90 institutional investors held Paratek Pharmaceuticals (PRTK) as of Q2 2016, up from 62 in Q1 2016.
  • Funds reported $245M of Paratek Pharmaceuticals stock for Q2 2016, up 14% quarter-over-quarter.
  • 33 funds opened new Paratek Pharmaceuticals positions in Q2 2016 and 5 closed out, a net change of +28 holders.
  • The largest Paratek Pharmaceuticals buyer in Q2 2016 was BVF Inc, an estimated $8.47M added.
  • The largest Paratek Pharmaceuticals seller in Q2 2016 was Fidelity Investments, an estimated $7.32M sold.

Based on aggregated 13F filings for Q2 2016.